Two Flap Innovations Lessen Need for Revision

BY TIMOTHY F. KIRN
Sacramento Bureau

Palm Desert, Calif. — An island pedicle flap can easily be elongated to accommodate facial anatomy and a pedicle graft for the ear’s conchal bowl can come from the back of the ear, two dermatologists said in “My Favorite Flap” at the annual meeting of the American Society for Dermatologic Surgery. The island pedicle flap is a modest, un

Famvir® (famciclovir) Tablets

Dosage

In adults, Famvir® tablets are administered as follows:

- 250 mg q.d. for treatment of primary genital herpes
- 250 mg t.i.d. for treatment of recurrent genital herpes
- 500 mg t.i.d. for suppression of recurrent genital herpes

In children over 12 years of age, Famvir® tablets are administered as follows:

- 125 mg q.d. for treatment of primary genital herpes
- 125 mg t.i.d. for treatment of recurrent genital herpes
- 250 mg t.i.d. for suppression of recurrent genital herpes

Usual Dosages

- For patients with normal renal function: 250 mg t.i.d. for suppression of recurrent genital herpes
- For patients with mild to moderate renal impairment: 125 mg t.i.d. for suppression of recurrent genital herpes
- For patients with severe renal impairment: 250 mg t.i.d. for suppression of recurrent genital herpes

Precautions

- Famvir® tablets should not be used in patients with a history of hypersensitivity to acyclovir or valacyclovir
- Famvir® tablets should not be used in patients with a history of neutropenia
- Famvir® tablets should not be used in patients with a history of thrombocytopenia

Contraindications

- Famvir® tablets should not be used in patients with a history of hypersensitivity to acyclovir or valacyclovir
- Famvir® tablets should not be used in patients with a history of neutropenia
- Famvir® tablets should not be used in patients with a history of thrombocytopenia

Adverse Reactions

- The most common adverse reactions reported in clinical studies were:
  - Headache: 20%
  - Nausea: 10%
  - Vomiting: 6%

- Other adverse reactions reported in clinical studies included:
  - Abdominal pain: 1%
  - Migraine: 1%
  - Mucocutaneous: 1%

- The incidence of adverse reactions was similar in patients treated with Famvir® tablets and placebo.

References


